Filtern
Volltext vorhanden
- ja (10)
Gehört zur Bibliographie
- ja (10)
Dokumenttyp
Sprache
- Englisch (10)
Schlagworte
- TRAIL (2)
- acute myeloid leukemia (2)
- apoptosis (2)
- 1994> (1)
- BCOR (1)
- BCORL1 (1)
- CD27 (1)
- CD40 (1)
- CD70 (1)
- CML (1)
- Cancer genetics (1)
- Genetics research (1)
- Kongreß (1)
- Millimeterwelle (1)
- San Diego <Calif. (1)
- T cells (1)
- alleles (1)
- allogeneic hematopoietic stem cell transplantation (1)
- cancer microenvironment (1)
- chronic myeloid leukemia (1)
- consortium (1)
- cytarabine dose (1)
- dendritic cells (1)
- drug treatment (1)
- elderly (1)
- genetic modifiers (1)
- genome-wide association (1)
- hormone-related protein (1)
- immunotherapy (1)
- investigators (1)
- loss-of-function (1)
- mammographic density (1)
- ovarian cancer (1)
- risk stratification (1)
- scFv (1)
- stem cell transplantation (1)
- survival (1)
- susceptibility loci (1)
- tumor subtypes (1)
- tumour immunology (1)
- tyrosine kinase inhibitors (1)
Institut
- Medizinische Klinik und Poliklinik II (4)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (2)
- Physikalisches Institut (2)
- Frauenklinik und Poliklinik (1)
- Institut für Humangenetik (1)
- Institut für Virologie und Immunbiologie (1)
- Kinderklinik und Poliklinik (1)
- Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie (1)
- Medizinische Klinik und Poliklinik I (1)
- Theodor-Boveri-Institut für Biowissenschaften (1)
EU-Projektnummer / Contract (GA) number
- 223175 (1)
Background: The combination of intermediate-dose cytarabine plus mitoxantrone (IMA) can induce high complete remission rates with acceptable toxicity in elderly patients with acute myeloid leukemia (AML). We present the final results of a randomized-controlled trial comparing IMA with the standard 7+3 induction regimen consisting of continuous infusion cytarabine plus daunorubicin (DA).
Patients and methods: Patients with newly diagnosed AML>60 years were randomized to receive either intermediate-dose cytarabine (1000 mg/m(2) twice daily on days 1, 3, 5, 7) plus mitoxantrone (10 mg/m(2) days 1-3) (IMA) or standard induction therapy with cytarabine (100 mg/m(2) continuously days 1-7) plus daunorubicin (45 mg/m(2) days 3-5) (DA). Patients in complete remission after DA received intermediate-dose cytarabine plus amsacrine as consolidation treatment, whereas patients after IMA were consolidated with standard-dose cytarabine plus mitoxantrone.
Results: Between February 2005 and October 2009, 485 patients were randomized; 241 for treatment arm DA and 244 for IMA; 76% of patients were >65 years. The complete response rate after DA was 39% [95% confidence interval (95% CI): 33-45] versus 55% (95% CI: 49-61) after IMA (odds ratio 1.89, P = 0.001). The 6-week early-death rate was 14% in both arms. Relapse-free survival curves were superimposable in the first year, but separated afterwards, resulting in 3-year relapse-free survival rates of 29% versus 14% in the DA versus IMA arms, respectively (P = 0.042). The median overall survival was 10 months in both arms (P = 0.513).
Conclusion: The dose escalation of cytarabine in induction therapy lead to improved remission rates in the elderly AML patients. This did not translate into a survival advantage, most likely due to differences in consolidation treatment. Thus, effective consolidation strategies need to be further explored. In combination with an effective consolidation strategy, the use of intermediate-dose cytarabine in induction may improve curative treatment for elderly AML patients.